SCHEMBL12980388

SCHEMBL12980388

O=C(Nc1ccc(-c2nc3ccccc3s2)c(Cl)c1)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.65
▸ TP53 P04637 4/20 0.65
▸ RXFP1 Q9HBX9 3/20 0.65
▸ POLB P06746 2/20 0.65
▸ RAB9A P51151 3/20 0.62
▸ NPC1 O15118 2/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.61
▸ THRB P10828 2/20 0.58
▸ MEN1 O00255 5/20 0.57
▸ KMT2A Q03164 5/20 0.57
▸ ALDH1A1 P00352 3/20 0.56
▸ LMNA P02545 2/20 0.56
▸ HPGD P15428 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ BLM P54132 1/20 0.50
▸ EGFR P00533 1/20 0.49
▸ INSR P06213 1/20 0.49
▸ IGF1R P08069 1/20 0.49
▸ PDGFRB P09619 1/20 0.49
▸ SRC P12931 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12980863 0.84 SMN1; SMN2 (0.67) MAPTTP53RXFP1POLBRAB9A
SCHEMBL16602332 0.84 MAPT (0.82) MAPTTP53RXFP1POLBRAB9A
SCHEMBL12963451 0.83 RAB9A (0.69) MAPTTP53RXFP1POLBRAB9A
SCHEMBL12980741 0.83 SMN1; SMN2 (0.65) MAPTTP53RXFP1POLBRAB9A
SCHEMBL12980452 0.82 MAPT (0.65) MAPTTP53RXFP1POLBRAB9A
SCHEMBL1074520 0.81 TP53 (0.80) MAPTTP53RXFP1POLBRAB9A
SCHEMBL12980557 0.80 MAPT (0.66) MAPTTP53RXFP1POLBRAB9A
SCHEMBL12963207 0.78 SMN1; SMN2 (0.78) MAPTTP53RXFP1POLBRAB9A
SCHEMBL4910770 0.77 RAB9A (1.00) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL12553629 0.77 MEN1 (0.74) MAPTRAB9ASMN1; SMN2THRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150150852-A1 TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2015-06-04 — — US disclosed
US-8993604-B2 Treatment and prevention of dengue virus infections SIGA TECHNOLOGIES, INC. (US) 2015-03-31 — — US disclosed
US-20120258079-A1 Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. 2012-10-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150852-A1 TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS HAVCR2, TTPA, CHIA MAPT 118/4885TP53 2739/4885RXFP1 4348/4885
US-20120258079-A1 Treatment and Prevention of Dengue Virus Infections HAVCR2, TTPA, CHIA MAPT 118/4885TP53 2739/4885RXFP1 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback